Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: An open-label, phase 2 trial

Conclusions: Combination therapy of camrelizumab and albumin-bound paclitaxel and carboplatin shows promising efficacy and manageable toxicities in patients with recurrent or metastatic cervical cancer.

Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Xiaoling Zhang Jinlong Chen Naifu Liu Qian Wang Qian Wu Fufeng Gao Yingchun Sang Ping Wang Source Type: research